GSPT2 (G1 to S phase transition protein 2) has emerged as a critical regulator of the cell cycle and has garnered increased attention for its role in tumor biology in recent years. This review explores the multifaceted functions of GSPT2, highlighting its involvement in cell cycle regulation and signaling pathways, as well as its potential as a tumor biomarker. By analyzing the latest research findings, we examine the expression patterns of GSPT2 across various tumor types and its correlation with clinical outcomes, underscoring its significance in tumor initiation and progression. Furthermore, we discuss the prospects of GSPT2 as a therapeutic target, providing new insights for future research directions.
References
[1]
Leal-Esteban, L.C. and Fajas, L. (2020) Cell Cycle Regulators in Cancer Cell Metabolism. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1866, Article 165715. https://doi.org/10.1016/j.bbadis.2020.165715
[2]
Dang, F., Nie, L. and Wei, W. (2020) Ubiquitin Signaling in Cell Cycle Control and Tumorigenesis. Cell Death & Differentiation, 28, 427-438. https://doi.org/10.1038/s41418-020-00648-0
[3]
Wang, Z., Ren, M., Liu, W., Wu, J. and Tang, P. (2024) Role of Cell Division Cycle-Associated Proteins in Regulating Cell Cycle and Promoting Tumor Progression. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1879, Article 189147. https://doi.org/10.1016/j.bbcan.2024.189147
[4]
Greil, C., Engelhardt, M. and Wäsch, R. (2022) The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy. Frontiers in Genetics, 13, Article 941565. https://doi.org/10.3389/fgene.2022.941565
[5]
Kashyap, D., Garg, V.K., Sandberg, E.N., Goel, N. and Bishayee, A. (2021) Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis. Pharmaceutics, 13, Article 569. https://doi.org/10.3390/pharmaceutics13040569
[6]
Jones, M.J. and Jones, M.C. (2024) Cell Cycle Control by Cell-Matrix Interactions. Current Opinion in Cell Biology, 86, Article 102288. https://doi.org/10.1016/j.ceb.2023.102288
[7]
Liu, W., Ma, N., Gao, X., Liu, W., Jia, J., Tang, L., et al. (2019) Role of GSPT1 and GSPT2 Polymorphisms in Different Outcomes Upon Hepatitis B Virus Infection and Prognosis to Lamivudine Therapy. Bioscience Reports, 39, BSR20181668. https://doi.org/10.1042/bsr20181668
[8]
Al-Shehhi, H., Gabr, A., Al-Haddabi, I., Tena, R., Baquero, A., Al-Maamari, W., et al. (2019) Further Clinical and Molecular Delineation of Xp11.22 Deletion Syndrome: A Case Report. Oman Medical Journal, 34, 460-463. https://doi.org/10.5001/omj.2019.83
[9]
Hansen, L.L., Jakobsen, C.G. and Justesen, J. (1999) Assignment of the Human Peptide Chain Release Factor 3 (GSPT2) to Xp11.23→p11.21 and of the Distal Marker DXS1039 by Radiation Hybrid Mapping. Cytogenetic and Genome Research, 86, 250-251. https://doi.org/10.1159/000015353
[10]
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., et al. (2022) A Novel Cereblon E3 Ligase Modulator with Antitumor Activity in Gastrointestinal Cancer. Bioorganic Chemistry, 119, Article 105505. https://doi.org/10.1016/j.bioorg.2021.105505
[11]
Zhouravleva, G., Schepachev, V., Petrova, A., Tarasov, O. and Inge-Vechtomov, S. (2006) Evolution of Translation Termination Factor eRF3: Is GSPT2 Generated by Retrotransposition of GSPT1’s mRNA? IUBMB Life, 58, 199-202. https://doi.org/10.1080/15216540600686862
[12]
Le Goff, C., Zemlyanko, O., Moskalenko, S., Berkova, N., Inge‐Vechtomov, S., Philippe, M., et al. (2002) Mouse GSPT2, but Not GSPT1, Can Substitute for Yeast eRF3 in vivo. Genes to Cells, 7, 1043-1057. https://doi.org/10.1046/j.1365-2443.2002.00585.x
[13]
Roy, B., Roy, S., Kundu, M., Maji, S., Pal, B., Mandal, M., et al. (2021) Ground-State Proton-Transfer (GSPT)-Assisted Enhanced Two-Photon Uncaging from a Binol-Based AIE-Fluorogenic Phototrigger. Organic Letters, 23, 2308-2313. https://doi.org/10.1021/acs.orglett.1c00445
[14]
Hoshino, S., Hosoda, N., Araki, Y., et al. (1999) Novel Function of the Eukaryotic Polypeptide-Chain Releasing Factor 3 (eRF3/GSPT) in the mRNA Degradation Pathway. Biochemistry, 64, 1367-1372.
[15]
Xian, F., Zhao, C., Huang, C., Bie, J. and Xu, G. (2023) The Potential Role of CDC20 in Tumorigenesis, Cancer Progression and Therapy: A Narrative Review. Medicine, 102, e35038. https://doi.org/10.1097/md.0000000000035038
[16]
Chen, X., Yang, C., Wang, W., He, X., Sun, H., Lyu, W., et al. (2023) Exploration of Prognostic Genes and Risk Signature in Breast Cancer Patients Based on RNA Binding Proteins Associated with Ferroptosis. Frontiers in Genetics, 14, Article 1025163. https://doi.org/10.3389/fgene.2023.1025163
[17]
Brooks, R.F. (2021) Cell Cycle Commitment and the Origins of Cell Cycle Variability. Frontiers in Cell and Developmental Biology, 9, Article 698066. https://doi.org/10.3389/fcell.2021.698066
[18]
Lataster, L., Huber, H.M., Böttcher, C., Föller, S., Takors, R. and Radziwill, G. (2023) Cell Cycle Control by Optogenetically Regulated Cell Cycle Inhibitor Protein P21. Biology, 12, Article 1194. https://doi.org/10.3390/biology12091194
[19]
Chang, Y., Keramatnia, F., Ghate, P.S., Nishiguchi, G., Gao, Q., Iacobucci, I., et al. (2023) The Orally Bioavailable GSPT1/2 Degrader SJ6986 Exhibits in vivo Efficacy in Acute Lymphoblastic Leukemia. Blood, 142, 629-642. https://doi.org/10.1182/blood.2022017813
[20]
Thakur, A., Xu, H., Wang, Y., Bollig, A., Biliran, H. and Liao, J.D. (2005) The Role of X-Linked Genes in Breast Cancer. Breast Cancer Research and Treatment, 93, 135-143. https://doi.org/10.1007/s10549-005-4516-0
[21]
Zhou, Y., Kang, Y., Chen, C., Xu, F., Wang, H. and Jin, R. (2018) Combination of TNM Staging and Pathway Based Risk Score Models in Patients with Gastric Cancer. Journal of Cellular Biochemistry, 119, 3608-3617. https://doi.org/10.1002/jcb.26563
[22]
Suski, J.M., Braun, M., Strmiska, V. and Sicinski, P. (2021) Targeting Cell-Cycle Machinery in Cancer. Cancer Cell, 39, 759-778. https://doi.org/10.1016/j.ccell.2021.03.010
[23]
Hernandez, Y., Shpak, M., Duarte, T.T., Mendez, T.L., Maldonado, R.A., Roychowdhury, S., et al. (2008) Novel Role of Sphingolipid Synthesis Genes in Regulating Giardial Encystation. Infection and Immunity, 76, 2939-2949. https://doi.org/10.1128/iai.00116-08
[24]
Li, M., Wang, J., Yang, L., Gao, P., Tian, Q. and Liu, D. (2014) eRF3B, a Biomarker for Hepatocellular Carcinoma, Influences Cell Cycle and Phosphoralation Status of 4E-BP1. PLOS ONE, 9, e86371. https://doi.org/10.1371/journal.pone.0086371
[25]
Xiao, R., Gao, Y., Shen, Q., Li, C., Chang, W. and Chai, B. (2013) Polypeptide Chain Release Factor eRF3 Is a Novel Molecular Partner of Survivin. Cell Biology International, 37, 359-369. https://doi.org/10.1002/cbin.10043
